LONDON--(BUSINESS WIRE)--Regulatory News:
AstraZeneca (STO:AZN)(LSE:AZN):
Revenue for the full year was down 2 percent at constant exchange rates (CER) at $33,591 million.
-Strong double-digit sales growth at CER for Crestor, Seroquel XR and Symbicort; Emerging Markets revenue increased by 10 percent at CER in the fourth quarter and for the full year.
